document type sequence filename description text html head title title head body bgcolor white style margin margin bottom font size font family time roman align right exhibit style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign align center style border solid padding left style margin margin bottom font size font family time roman align center confidential material omitted filed separately with style margin margin bottom font size font family time roman align center security exchange commission double asterisk denote omission valign bottom valign bottom nbsp valign bottom align right execution nbsp copy nowrap valign bottom nbsp nbsp table style margin margin bottom font size font family time roman align center research exclusive option agreement style margin margin bottom text indent font size font family time roman this research exclusive option agreement this agreement entered into november nbsp effective date between ophthotech corporation delaware corporation with principal office penn plaza style font size vertical align floor york york ophthotech aveo pharmaceutical delaware corporation with principal office east kendall street cambridge massachusetts aveo aveo ophthotech referred herein each individually party collectively party style margin margin bottom font size font family time roman align center recital style margin margin bottom text indent font size font family time roman whereas aveo defined herein have previously entered into agreement defined herein under which they have collaborated development manufacture commercialization product incorporating proprietary compound known tivozanib treatment cancer with aveo holding right develop commercialize such product outside asia style margin margin bottom text indent font size font family time roman whereas ophthotech engaged discovery development commercialization pharmaceutical product treatment related macular degeneration other disease style margin margin bottom text indent font size font family time roman whereas tivozanib vascular endothelial growth factor vegf receptor inhibitor vegf receptor inhibitor believed have therapeutic utility patient with style margin margin bottom text indent font size font family time roman whereas ophthotech interested exploring whether product incorporating tivozanib alone combination with other therapeutic agent have therapeutic utility patient with aveo willing permit ophthotech conduct such exploration subject term condition this agreement style margin margin bottom text indent font size font family time roman whereas ophthotech interested obtaining exclusive option obtain from aveo exclusive right license develop commercialize product incorporating tivozanib field defined herein outside asia aveo willing grant such option right license ophthotech while retaining right outside field more particularly forth below style margin margin bottom text indent font size font family time roman therefore consideration foregoing premise covenant obligation forth this agreement party agree follows style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center definition style margin margin bottom text indent font size font family time roman initially capitalized term below this article have following meaning used throughout this agreement derivative form these defined term shall interpreted accordingly style margin margin bottom text indent font size font family time roman affiliate mean with respect party entity that directly indirectly through more intermediary control controlled under common control with such party this purpose control mean ownership fifty percent nbsp more voting security entitled elect director management entity actual power elect direct management policy entity whether contract otherwise style margin margin bottom text indent font size font family time roman meaning forth recital style margin margin bottom text indent font size font family time roman aveo indemnitees meaning forth section style margin margin bottom text indent font size font family time roman aveo material mean tivozanib hydrochloride drug substance quantity forth section nbsp such additional quantity such material aveo provide pursuant section style margin margin bottom text indent font size font family time roman cgmp mean applicable requirement detailed current good manufacturing practice regulation part rule governing medicinal product european community volume good manufacturing practice medicinal product each amended from time time style margin margin bottom text indent font size font family time roman clinical efficacy milestone mean style margin margin bottom text indent font size font family time roman clinical efficacy milestone payment trigger date mean earlier occur nbsp december nbsp nbsp later occur nbsp achievement clinical efficacy milestone nbsp earlier nbsp date twelve nbsp month after party agreement form substance agreement amendment pursuant section nbsp nbsp date ninety nbsp after aveo enters into agreement amendment pursuant section style margin margin bottom text indent font size font family time roman commercially reasonable effort mean level effort expertise resource that consistent with level effort expertise resource that biopharmaceutical company size resource comparable those ophthotech would generally devote conduct research relating product similar market potential profit potential strategic value similar stage development based condition then prevailing including issue safety efficacy product profile competitiveness alternative product marketplace likely timing product entry into relevant market patent other proprietary position product cost likelihood obtaining regulatory approval other relevant scientific technical commercial factor style margin margin bottom text indent font size font family time roman compound mean chloro dimethoxyquinolin oxyphenyl methyl oxazol urea otherwise known tivozanib style margin margin bottom text indent font size font family time roman confidential information mean information received either party from other party disclosed either party other party pursuant this agreement each case which information disclosed under circumstance reasonably indicating that confidential between party agreement confidential information style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman aveo notwithstanding foregoing confidential information shall include information that each case demonstrated competent written documentation style margin margin bottom text indent font size font family time roman publicly disclosed made generally available public disclosing party either before after becomes known receiving party style margin margin bottom text indent font size font family time roman known receiving party without obligation keep confidential prior date disclosure disclosing party style margin margin bottom text indent font size font family time roman subsequently disclosed receiving party third party lawfully possession thereof without obligation keep confidential without breach such third party obligation confidentiality style margin margin bottom text indent font size font family time roman been publicly disclosed made generally available public other than through omission receiving party breach this agreement style margin margin bottom text indent font size font family time roman been independently developed receiving party without application disclosing party confidential information competent written proof which must contemporaneous with such independent development style margin margin bottom text indent font size font family time roman control mean with respect know patent other intellectual property right possession party directly through affiliate controlled such party whether ownership license other than pursuant this agreement ability grant license sublicense provided herein without violating term existing written agreement with third party style margin margin bottom text indent font size font family time roman debtor meaning forth section style margin margin bottom text indent font size font family time roman dispute meaning forth section style margin margin bottom text indent font size font family time roman dollar mean united state dollar style margin margin bottom text indent font size font family time roman excluded territory mean following country their respective territory possession afghanistan bahrain bangladesh bhutan brunei cambodia india indonesia iran iraq israel japan jordan kuwait lebanon malaysia maldives mongolia myanmar nepal north korea oman pakistan people republic china including hong kong macao philippine qatar saudi arabia singapore south korea lanka syria taiwan thailand timor leste turkey united arab emirate vietnam yemen style margin margin bottom text indent font size font family time roman mean food drug administration successor entity style margin margin bottom text indent font size font family time roman field mean diagnosis prevention treatment oncologic disease condition human style margin margin bottom text indent font size font family time roman force majeure meaning forth section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman mean investigational drug application defined federal food drug cosmetic regulation promulgated thereunder united state comparable filing other jurisdiction filing with regulatory authority that must made prior commencing clinical testing human each case with respect compound field style margin margin bottom text indent font size font family time roman invention mean patentable invention first conceived reduced practice behalf ophthotech affiliate permitted sublicensees course option period research style margin margin bottom text indent font size font family time roman mean kyowa hakko kirin japanese corporation with principal office ohtemachi chiyoda tokyo japan style margin margin bottom text indent font size font family time roman agreement mean that certain license agreement entered into december nbsp between aveo amended from time time style margin margin bottom text indent font size font family time roman agreement amendment mean amendment agreement focusing matter forth exhibit form substance mutually agreed party before date nbsp month after effective date style margin margin bottom text indent font size font family time roman indemnitees meaning forth section style margin margin bottom text indent font size font family time roman know mean nbsp information technique data invention practice method process knowledge know skill experience technical data test result including pharmacological toxicological clinical analytical quality control data regulatory submission correspondence communication marketing distribution pricing cost manufacturing patent legal data description nbsp composition matter assay other material style margin margin bottom text indent font size font family time roman license agreement mean license agreement that party would enter into upon ophthotech exercise option effective date outline term such license agreement attached hereto exhibit pursuant section nbsp hereof party shall negotiate good faith form substance license agreement during option period upon agreement definitive form such license agreement outline term forth exhibit will replaced with such definitive form license agreement style margin margin bottom text indent font size font family time roman licensed know mean know that controlled aveo during option period relates compound product containing compound method using including method administration testing foregoing article necessary useful practice such method excluding know licensed aveo after effective date which aveo would third party consideration aveo grant right thereunder ophthotech style margin margin bottom text indent font size font family time roman licensed patent mean patent controlled aveo during option period that claim otherwise cover compound product containing compound method making using including method administration testing foregoing such method excluding patent licensed aveo after effective date which aveo would third party consideration aveo grant right thereunder ophthotech style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman licensed technology mean both licensed patent licensed know style margin margin bottom text indent font size font family time roman loss meaning forth section style margin margin bottom text indent font size font family time roman dispute meaning forth section style margin margin bottom text indent font size font family time roman event meaning forth section style margin margin bottom text indent font size font family time roman ophthotech third party claim meaning forth section style margin margin bottom text indent font size font family time roman option meaning forth section style margin margin bottom text indent font size font family time roman option exercise date meaning forth section style margin margin bottom text indent font size font family time roman option period mean period commencing effective date ending latest nbsp date twelve nbsp month after achievement clinical efficacy milestone nbsp date ninety nbsp after clinical efficacy milestone payment trigger date nbsp date thirty nbsp after party agreement definitive form license agreement style margin margin bottom text indent font size font family time roman option period research mean research development activity field described exhibit including without limitation clinical study filing performance study avoidance doubt including clinical animal study notwithstanding human limitation field definition conducted ophthotech during option period such activity modified pursuant section nbsp provided that such activity shall include human clinical development oral formulation compound product containing compound unless otherwise mutually agreed party style margin margin bottom text indent font size font family time roman option period research territory mean country world other than those excluded territory together with territory possession such country that part excluded territory style margin margin bottom text indent font size font family time roman patent mean patent application patent anywhere world including following kind provisional utility divisional continuation continuation part substitution application utility issue examination renewal extended patent patent addition supplementary protection certificate restoration patent term other similar right style margin margin bottom text indent font size font family time roman study mean phase proof concept clinical trial licensed product patient with that described exhibit style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman regulatory authority mean national without limitation supra national without limitation european commission council european union european medicine agency regional state local regulatory agency department bureau commission council other governmental entity jurisdiction world involved granting marketing approval biological pharmaceutical product style margin margin bottom text indent font size font family time roman research material meaning forth section style margin margin bottom text indent font size font family time roman safety data mean nbsp adverse event information nbsp other safety information required nbsp more regulatory authority reported such regulatory authority under applicable style margin margin bottom text indent font size font family time roman term meaning forth section style margin margin bottom text indent font size font family time roman third party mean person entity other than party affiliate party style margin margin bottom text indent font size font family time roman third party claim meaning forth section style margin margin bottom text indent font size font family time roman vegf meaning forth recital style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center option period activity style margin margin bottom text indent font size font family time roman transfer aveo material aveo shall provide ophthotech cost ophthotech research grade tivozanib research material ophthotech solely conduct option period research within fifteen nbsp after effective date thereafter aveo shall upon reasonable written request ophthotech delivered advance expected delivery shipment within united state advance expected delivery shipment outside united state make available ophthotech cost ophthotech such additional quantity aveo material ophthotech reasonably require solely conducting option period research provided however that aveo shall obligated hereunder supply ophthotech with more than aveo material aggregate aveo hereby represents warrant ophthotech that least aveo material inventory effective date with remaining shelf life during option period aveo shall maintain sufficient inventory aveo material meet obligation ophthotech under this section nbsp aveo shall place aveo material long term stability conduct stability testing such aveo material later than once every thereafter aveo shall promptly provide ophthotech result such testing ophthotech shall upon receipt thereof promptly review such result either nbsp confirm such result nbsp provide aveo with question regarding result which aveo shall promptly address event that stability testing data indicate that aveo material expected expire prior february nbsp aveo shall expense within nbsp month receipt such data make have made additional aveo material that meet specification forth exhibit have expiration date earlier than february nbsp further understood agreed that specification aveo material have been prepared aveo material oral formulation aveo shall have liability kind ophthotech failure such aveo material conform specification necessary ocular administration style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman aveo material ophthotech agrees aveo material solely option period research ophthotech exercise option thereof permitted under license agreement other purpose ophthotech undertakes aveo material safe manner compliance with professional standard applicable federal state local regulation ophthotech shall notify aveo ophthotech desire modify option period research material respect subject aveo consent unreasonably withheld delayed conditioned party shall update exhibit reflect such modification requested ophthotech style margin margin bottom text indent font size font family time roman restriction distribution aveo material ophthotech shall make aveo material available person other than ophthotech employee contractor performing option period research hereunder ophthotech exercise option activity permitted under license agreement such employee contractor shall bound obligation aveo material only manner permitted under this agreement ophthotech exercise option license agreement shall subject confidentiality obligation stringent than those specified section nbsp below license agreement applicable ophthotech shall remain responsible such employee contractor compliance with applicable term obligation this agreement style margin margin bottom text indent font size font family time roman diligence conducting option period research ophthotech shall commercially reasonable effort conduct option period research sole cost expense ophthotech sole exclusive liability aveo sole exclusive remedy failure ophthotech such effort conduct option period research shall aveo terminate option pursuant section nbsp before each year during option period ophthotech shall deliver aveo written report providing reasonable detail summary option period research activity prior calendar year including invention from that year status study applicable anticipated plan research development current calendar year addition time that mutually agreed party approximately month after delivery foregoing written report ophthotech shall provide aveo with presentation verbal report status option period research such presentation verbal report with given person meeting teleconference videoconference party mutually agree style margin margin bottom text indent font size font family time roman amendment agreement party acknowledge that negotiating agreement amendment prerequisite party negotiation mutually acceptable form license agreement pursuant section nbsp ophthotech exercise option accordingly party agree diligently negotiate between party form substance proposed agreement amendment before date that month after effective date thereafter aveo shall diligently promptly seek enter into such amendment with should require modification term proposed agreement amendment aveo shall discus such required change with ophthotech seek reach consensus with ophthotech before agreeing such change notwithstanding anything foregoing this agreement contrary between ophthotech aveo aveo shall solely responsible interaction with unless otherwise mutually agreed party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman negotiation definitive form license agreement party shall diligently good faith negotiate definitive form license agreement which shall among other thing contain financial other term attached hereto exhibit party will endeavor conclude negotiation later than later after aveo enters into agreement amendment with after clinical efficacy milestone upon conclusion such negotiation party shall attach such definitive form license agreement hereto exhibit place such initial outline term style margin margin bottom text indent font size font family time roman support aveo ophthotech from time time request reasonable assistance aveo support conduct option period research including manufacturing technology transfer activity aveo will commercially reasonable effort provide such agreed upon support activity ophthotech provided that ophthotech shall reimburse aveo reasonable cost expense incurred performing such agreed upon support activity beyond aggregate including without limitation compensation reasonable actual cost employee pocket expense within receipt invoice therefor style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center option grant style margin margin bottom text indent font size font family time roman grant option aveo hereby grant ophthotech exclusive option exercisable during option period enter into license agreement option subject term condition this agreement style margin margin bottom text indent font size font family time roman option period option shall exercisable ophthotech time during option period style margin margin bottom text indent font size font family time roman option exercise event ophthotech elect exercise option shall later than eastern time last option period deliver aveo written notice specifying that ophthotech elected exercise option date which ophthotech properly exercised option accordance with preceding sentence shall option exercise date purpose this agreement style margin margin bottom text indent font size font family time roman exclusivity option during period commencing effective date ending expiration option period aveo will nbsp neither offer grant license other right third party that would preclude aveo from being able grant right license ophthotech that contemplated exhibit discus negotiate with third party potential proposed transaction that entered into would prevent aveo from being able grant right license ophthotech that contemplated exhibit nbsp engage research development commercialization compound field other than requested ophthotech support ophthotech conduct option period research style margin margin bottom text indent font size font family time roman maintenance agreement during option period aveo shall commercially reasonable effort maintain agreement full force effect shall agree permit amendment termination thereof that would adversely affect ophthotech option right hereunder style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center payment style margin margin bottom text indent font size font family time roman option grant consideration grant option provision aveo aveo material ophthotech shall aveo five hundred thousand dollar within nbsp after effective date such amount shall refundable shall creditable against other amount hereunder style margin margin bottom text indent font size font family time roman submission milestone payment consideration grant option provision aveo aveo material ophthotech shall aveo time milestone payment million dollar within after filing acceptance first ophthotech purpose conducting human clinical study compound product containing compound accordance with exhibit such amount shall refundable shall creditable against other amount hereunder ophthotech shall also notify aveo filing acceptance such first within such payment period ophthotech shall promptly notify aveo achievement foregoing milestone style margin margin bottom text indent font size font family time roman clinical efficacy milestone payment consideration grant option provision aveo aveo material ophthotech shall aveo time milestone payment million dollar within after clinical efficacy milestone payment trigger date such amount shall refundable shall creditable against other amount hereunder ophthotech shall also notify aveo achievement clinical efficacy milestone within such after such achievement notwithstanding foregoing such payment shall payable ophthotech give aveo notice termination pursuant section nbsp prior date after clinical efficacy milestone payment trigger date whether such termination becomes effective prior date after clinical efficacy milestone payment trigger date style margin margin bottom text indent font size font family time roman option exercise consideration aveo exercise license agreement ophthotech shall aveo time option exercise payment million dollar plus milestone forth section nbsp such milestone then been previously paid option exercise within nbsp after delivery notice delivered pursuant section nbsp such amount shall refundable shall creditable against other amount hereunder time ophthotech exercise option clinical efficacy milestone payment trigger date occurred ophthotech shall milestone forth section nbsp after such option exercise such time clinical efficacy milestone payment trigger date occur license agreement remains effect such subsequent occurrence style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center license agreement requirement style margin margin bottom text indent font size font family time roman option period license grant subject term condition this agreement agreement aveo hereby grant ophthotech during option period exclusive royalty free license sublicense applicable under licensed technology option period research territory field with right sublicense except affiliate third party subcontractor engaged perform option period research solely extent necessary ophthotech perform option period research style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman agreement requirement ophthotech acknowledges that license granted pursuant section nbsp includes sublicenses know patent that have been licensed aveo pursuant agreement that such sublicenses subject term condition agreement ophthotech hereby agrees comply with term condition agreement applicable ophthotech sublicensee right thereunder including without limitation those term condition specified section nbsp agreement extent applicable which provision shall incorporated herein reference without limiting foregoing event conflict inconsistency between this agreement agreement party shall reasonably cooperate with another necessary with amend this agreement necessary comply with term condition agreement event disagreement regarding applicability term condition agreement sublicenses granted ophthotech hereunder ophthotech compliance therewith nbsp aveo sole discretion party unable agree resolution required cure resulting breach agreement based which notified aveo that intends terminate agreement terminate this agreement before applicable termination notice period agreement nbsp aveo termination this agreement shall aveo sole exclusive remedy ophthotech sole exclusive liability breach agreement resulting from underlying basis such disagreement inconsistency between term this agreement term condition agreement provided that aveo shall also have right seek specific performance enforce obligation ophthotech provide access deliver information data required agreement style margin margin bottom text indent font size font family time roman grant back license style margin margin bottom text indent font size font family time roman extent that invention know arising conduct behalf ophthotech option period research relates compound ophthotech hereby grant aveo irrevocable perpetual exclusive royalty free license with right grant sublicenses under such invention know patent claiming such invention know nbsp research develop sell offer sale import compound product containing compound excluded territory other than diagnosis prevention treatment human disease condition worldwide nbsp make have made compound product containing compound worldwide clinically test product containing compound anywhere world obtain data support application marketing approval excluded territory such license sublicensed accordance with section nbsp agreement extent agreement amendment executed includes term that permit party reduce otherwise limit scope foregoing grant back license such license shall automatically modified accordingly style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman extent that invention arising conduct behalf ophthotech option period research relates compound ophthotech hereby grant aveo irrevocable subject section nbsp term license agreement executed perpetual exclusive royalty free license with right grant sublicenses under patent claiming such invention aveo nbsp research develop sell offer sale import compound product containing compound outside field option period research territory nbsp research develop sell offer sale import compound product containing compound field option period research territory after option period ophthotech exercise option nbsp make have made compound product containing compound worldwide clinically test product containing compound anywhere world obtain data solely support application marketing approval option period research territory connection with activity permitted license granted clause nbsp nbsp above avoidance doubt license forth section nbsp include right access data other know ophthotech arising conduct option period research other than forth section nbsp extent agreement amendment executed includes term that permit party limit scope grant back license section nbsp grant back license aveo this section nbsp shall also automatically modified include such limitation style margin margin bottom text indent font size font family time roman ophthotech hereby grant aveo royalty free license with right grant sublicenses safety data connection with clinical development activity aveo outside field support application marketing approval compound product containing compound outside field ophthotech shall promptly event more than hour after knowledge serious adverse event provide aveo with safety data related such event prior initiation ophthotech first human clinical trial compound product containing compound party shall mutually agree writing detailed protocol regarding exchange safety data ongoing basis accordance with applicable style margin margin bottom text indent font size font family time roman inventorship inventorship invention will determined accordance with united state patent style margin margin bottom text indent font size font family time roman patent know each party hereby covenant that affiliate sublicensees applicable shall practice patent know licensed such party hereunder outside scope license granted such party under this agreement style margin margin bottom text indent font size font family time roman prosecution patent between aveo ophthotech aveo shall responsible have sole control over filing prosecution maintenance enforcement defense licensed patent worldwide basis expense style margin margin bottom text indent font size font family time roman notification infringement each party shall promptly notify other party writing notifying party reasonably belief that licensed patent being been infringed misappropriated option period research territory field third party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman reservation right implied license right title interest granted either party whether expressly implication under patent know other than those right license expressly granted this agreement style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center confidentiality publicity style margin margin bottom text indent font size font family time roman treatment confidential information during option period period year after option period such longer period required comply with aveo obligation under agreement confidential information that subject confidentiality provision agreement party receiving confidential information other party shall nbsp maintain confidence such confidential information same extent such party maintains most highly confidential proprietary information event than commercially reasonable effort nbsp disclose such confidential information third party without prior written consent other party nbsp such confidential information purpose except those permitted this agreement style margin margin bottom text indent font size font family time roman authorized disclosure notwithstanding section nbsp party disclose confidential information other party extent such disclosure reasonably necessary following instance style margin margin bottom text indent font size font family time roman filing prosecuting maintaining patent style margin margin bottom text indent font size font family time roman regulatory filing style margin margin bottom text indent font size font family time roman prosecuting defending litigation style margin margin bottom text indent font size font family time roman complying with applicable governmental regulation submitting information other governmental authority provided that receiving party required make public disclosure confidential information disclosing party extent legally will give reasonable advance notice disclosing party such disclosure will reasonable effort secure confidential treatment confidential information prior disclosure whether through protective order otherwise style margin margin bottom text indent font size font family time roman nbsp affiliate employee consultant agent accountant lawyer advisor investor actual potential sublicensees collaborator nbsp others order solely extent required exercise such party right fulfill obligation under this agreement agreement need know basis each whom nbsp nbsp prior disclosure must bound similar obligation confidentiality substantially equivalent scope those forth this article that reasonable duration view circumstance disclosure style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman publicity style margin margin bottom text indent font size font family time roman aveo will issue press release file with security exchange commission current report form each form with content forth exhibit following execution this agreement other publication news release other public announcement regarding execution term subject matter this agreement clarity publication news release other public announcement regarding development commercialization compound product containing compound outside field shall first reviewed approved both party absence such required approval such subsequent publication news release other public announcement shall include information beyond that approved initial press release form style margin margin bottom text indent font size font family time roman term this agreement shall treated confidential information both party style margin margin bottom margin left text indent font size font family time roman such term disclosed party individual entity covered section nbsp section nbsp except above each whom prior disclosure must bound similar obligation confidentiality substantially equivalent scope those forth this article style margin margin bottom margin left text indent font size font family time roman disclosure term this agreement other confidential information received from other party also made actual potential banker lender investor actual potential sublicensees collaborator disclosing party bound obligation confidentiality substantially equivalent scope those forth this article provided however that ophthotech shall permitted disclose term agreement style margin margin bottom margin left text indent font size font family time roman addition time party legally required file copy this agreement with connection with such party regular reporting obligation public company such party shall attempt obtain confidential treatment economic trade secret information which such treatment reasonably available accordance with applicable regulation practice that filing party shall least advance such filing provide other party with draft redaction agreement which confidential treatment will sought incorporate such other party comment additional term would like redacted seek confidential treatment such additional term except only limited circumstance where confidential treatment manifestly unavailable style margin margin bottom margin left text indent font size font family time roman party acknowledge that aveo required under section nbsp agreement obtain prior approval unreasonably withheld conditioned delayed with respect publication news release public announcement regarding term agreement good faith effort notify advance significant public announcement regarding licensed product performance achievement either party required file copy this agreement with provide least advance such filing with draft redaction this agreement relates agreement which confidential treatment will sought incorporate comment additional term would like redacted seek confidential treatment such additional term except only limited circumstance where confidential treatment manifestly unavailable ophthotech shall reasonably cooperate with aveo with respect aveo effort comply with foregoing obligation under agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center representation warranty style margin margin bottom text indent font size font family time roman general representation warranty each party represents warrant covenant other that style margin margin bottom text indent font size font family time roman duly organized validly existing under state country incorporation full corporate power authority enter into this agreement carry provision hereof style margin margin bottom text indent font size font family time roman duly authorized execute deliver this agreement perform obligation hereunder person person executing this agreement behalf have been duly authorized requisite corporate action style margin margin bottom text indent font size font family time roman this agreement legally binding upon enforceable accordance with term execution delivery performance this agreement conflict with agreement instrument understanding oral written which party which bound violate material regulation court governmental body administrative other agency having jurisdiction over style margin margin bottom text indent font size font family time roman granted shall grant during term agreement right third party which would conflict with right granted other party hereunder shall have time performance maintained shall maintain keep full force effect agreement necessary perform obligation hereunder style margin margin bottom text indent font size font family time roman aware action suit inquiry investigation instituted governmental agency which question threatens validity this agreement style margin margin bottom text indent font size font family time roman aveo warranty aveo represents warrant ophthotech that effective date style margin margin bottom text indent font size font family time roman supplied ophthotech with true correct complete copy agreement style margin margin bottom text indent font size font family time roman neither aveo affiliate aveo knowledge received written notice claim that patent trade secret right owned controlled third party would infringed misappropriated sale offer sale importation compound product containing compound field style margin margin bottom text indent font size font family time roman aveo knowledge nbsp proceeding pending threatened that challenge aveo ownership control applicable licensed patent nbsp licensed patent subject pending threatened examination opposition interference litigation proceeding style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman aveo knowledge licensed technology being infringed misappropriated third party except where such infringement would materially affect right granted ophthotech hereunder style margin margin bottom text indent font size font family time roman other than disclosed periodic report filed aveo with there action claim demand suit proceeding arbitration grievance citation summons subpoena nature civil criminal regulatory otherwise equity pending aveo knowledge threatened against aveo affiliate relating licensed patent licensed know transaction contemplated this agreement style margin margin bottom text indent font size font family time roman none licensed patent require payment consideration aveo affiliate ophthotech affiliate third party excluding connection with grant right ophthotech affiliate under this agreement exercise such right ophthotech affiliate style margin margin bottom text indent font size font family time roman aveo material provided aveo ophthotech hereunder other than research material nbsp have been manufactured accordance with applicable regulation regulatory authority united state european union japan canada including with respect aveo material used human clinical trial cgmp nbsp time delivery ophthotech conform their specification forth exhibit aveo knowledge research material suitable intended purpose conducting animal study style margin margin bottom text indent font size font family time roman ophthotech warranty ophthotech represents warrant aveo that effective date have vegf receptor inhibitor defined below stage development commercialization diagnosis prevention treatment form cancer purpose this section nbsp term vegf receptor inhibitor mean composition matter including small molecule other compound peptide protein where primary mechanism action described below such composition through binding whether covalently including ionically electrostatically through hydrophobic interaction through hydrogen bond covalently more vegf vegf vegf vegf vegf receptor vegf receptor vegf receptor given composition multiple mechanism action binding inhibiting multiple kinase then such composition shall deemed have primary mechanism action binding more vegfs vegf receptor specified above only such composition bind least specifically vegf vegf receptor other kinase which such composition exerts other mechanism action otherwise such composition shall vegf receptor inhibitor style margin margin bottom text indent font size font family time roman warranty debarment each ophthotech aveo represents warrant covenant that course development activity related compound such party prior effective date used shall during option period employee consultant been debarred regulatory authority best such party knowledge subject debarment proceeding regulatory authority style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman disclaimer concerning technology except otherwise expressly provided herein patent know provided each party hereunder provided each party expressly disclaims warranty kind express implied including without limitation warranty design merchantability fitness particular purpose noninfringement intellectual property right third party arising from course dealing usage trade practice case with respect thereto without limiting generality foregoing each party expressly warrant nbsp success activity performed pursuant this agreement nbsp safety efficacy usefulness purpose patent know provides under this agreement subject matter them style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center indemnification style margin margin bottom text indent font size font family time roman indemnification ophthotech style margin margin bottom text indent font size font family time roman ophthotech shall indemnify hold harmless defend aveo each affiliate their respective officer director employee agent each their respective successor heir assigns collectively aveo indemnitees from against loss damage liability judgment fine amount paid settlement expense cost defense including reasonable attorney witness collectively loss resulting from demand claim action proceeding brought initiated third party each third party claim against aveo indemnitees extent that such third party claim arises style margin margin bottom margin left text indent font size font family time roman breach alleged breach representation warranty covenant ophthotech article this agreement style margin margin bottom margin left text indent font size font family time roman negligence willful misconduct violation applicable regulation ophthotech indemnitee style margin margin bottom margin left text indent font size font family time roman conduct option period research ophthotech indemnitees including without limitation research development manufacture storage handling aveo material compound product containing compound style margin margin bottom font size font family time roman provided each case that nbsp aveo indemnitees comply with procedure forth section nbsp nbsp such indemnity shall apply extent aveo indemnification obligation pursuant section nbsp such loss ophthotech shall require equivalent indemnification aveo indemnitees clause nbsp foregoing sentence from each sublicensee such sublicensee activity described such clause style margin margin bottom text indent font size font family time roman ophthotech shall indemnify hold harmless defend affiliate affiliate sublicensees respective officer director employee agent each foregoing entity collectively indemnitees from style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman against loss resulting from third party claim against indemnitees extent that such third party claim arises conduct option period research ophthotech indemnitees including without limitation research development manufacture storage handling aveo material compound product containing compound provided that nbsp indemnitees comply with procedure forth section nbsp agreement nbsp such indemnity shall apply extent indemnification obligation pursuant section nbsp agreement such loss style margin margin bottom text indent font size font family time roman indemnification aveo style margin margin bottom text indent font size font family time roman aveo shall indemnify hold harmless defend ophthotech ophthotech affiliate ophthotech affiliate sublicensees respective officer director employee agent each foregoing entity collectively ophthotech indemnitees from against loss resulting from third party claim against them extent that such third party claim arises style margin margin bottom margin left text indent font size font family time roman breach alleged breach representation warranty covenant aveo article this agreement style margin margin bottom margin left text indent font size font family time roman negligence willful misconduct violation applicable regulation aveo indemnitee style margin margin bottom margin left text indent font size font family time roman except otherwise provided section nbsp development manufacture storage handling shipping sale offer sale importation other commercialization compound product containing compound aveo indemnitees outside field outside option period research territory style margin margin bottom font size font family time roman provided each case that nbsp ophthotech indemnitees comply with procedure forth section nbsp nbsp such indemnity shall apply extent ophthotech indemnification obligation pursuant section nbsp such loss style margin margin bottom text indent font size font family time roman addition party acknowledge that pursuant section nbsp agreement agreed indemnify hold harmless defend aveo sublicensees respective officer director employee agent foregoing entity from against loss resulting from third party claim against aveo sublicensees extent that such third party claim arises style margin margin bottom margin left text indent font size font family time roman breach alleged breach representation warranty covenant article agreement style margin margin bottom margin left text indent font size font family time roman negligence willful misconduct kirin indemnitee defined agreement style margin margin bottom font size font family time roman provided each case that nbsp aveo applicable sublicensee comply with procedure forth section nbsp agreement nbsp such indemnity shall apply extent that aveo indemnification obligation such loss pursuant section nbsp agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman ophthotech sublicensee aveo seek indemnified with respect third party claim forth section nbsp above pursuant section nbsp agreement ophthotech third party claim ophthotech shall promptly notify aveo thereof order ensure compliance with procedure forth section nbsp agreement each party shall comply with procedure forth below style margin margin bottom margin left text indent font size font family time roman extent that aveo receives prompt notice from ophthotech ophthotech third party claim aveo shall commercially reasonable effort provide with prompt notice such ophthotech third party claim giving rise indemnification obligation pursuant section nbsp agreement exclusive ability defend with reasonable cooperation aveo ophthotech expense through basis settle such claim party acknowledge that pursuant section nbsp agreement agreed enter into settlement damage other than monetary damage without aveo written consent which consent shall given aveo unless until party mutually agree such agreement unreasonably withheld delayed conditioned either party style margin margin bottom margin left text indent font size font family time roman party acknowledge that pursuant section nbsp agreement aveo right participate defense claim suit that been assumed under section nbsp agreement requested ophthotech aveo shall commercially reasonable effort obtain consent ophthotech participation along with aveo defense claim suit with respect ophthotech third party claim that been assumed under section nbsp agreement being understood that participation ophthotech such suit claim shall conducted ophthotech expense with counsel ophthotech choice style margin margin bottom margin left text indent font size font family time roman party acknowledge that pursuant section nbsp agreement aveo agree application section nbsp section nbsp agreement particular ophthotech third party claim which agreement shall given withheld aveo unless until party mutually agree such agreement unreasonably withheld delayed conditioned either party aveo conduct separate defense such ophthotech third party claim such case between aveo ophthotech aveo shall have exclusive right assume defense such ophthotech third party claim including settlement thereof provided that aveo shall enter into settlement damage other than monetary damage without ophthotech written consent which shall unreasonably withheld delayed conditioned ophthotech shall have right participate such defense ophthotech expense using counsel ophthotech choice party acknowledge that aveo reserve right shall commercially reasonable effort claim indemnity from accordance with section nbsp agreement upon resolution underlying ophthotech third party claim style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman procedure eligible aveo indemnitees ophthotech indemnitees applicable indemnified hereunder party shall provide indemnifying party with prompt notice third party claim giving rise indemnification obligation pursuant this article exclusive ability defend with reasonable cooperation indemnified party defending party expense through basis settle such claim provided however that indemnifying party shall enter into settlement damage other than monetary damage without indemnified party written consent such consent unreasonably withheld delayed conditioned indemnified party shall have right participate expense with counsel choice defense claim suit that been assumed indemnifying party party agree application section particular third party claim party conduct separate defense such third party claim each party reserve right claim indemnity from other accordance with section above upon resolution underlying claim notwithstanding provision this section nbsp requiring indemnified party tender indemnifying party exclusive ability defend such claim suit style margin margin bottom text indent font size font family time roman insurance ophthotech shall procure maintain insurance self insurance including product liability insurance adequate cover obligation hereunder which consistent with normal business practice prudent company similarly situated time during which licensed product being clinically tested human subject commercially distributed sold behalf ophthotech minimum ophthotech shall insured dollar cover obligation under this agreement understood that such insurance self insurance shall construed create limit ophthotech liability with respect indemnification obligation under this article ophthotech shall provide aveo with written evidence such insurance self insurance upon request ophthotech shall provide aveo with written notice least prior cancellation renewal material change such insurance self insurance which materially adversely affect right aveo hereunder style margin margin bottom text indent font size font family time roman limitation liability except extent such party required indemnify other party under this article respect breach article neither party respective affiliate licensee including sublicensees other licensee shall liable special incidental exemplary consequential punitive damage including lost profit arising connection with this agreement whether contract warranty tort including negligence strict liability otherwise style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center term termination style margin margin bottom text indent font size font family time roman term this agreement shall become effective effective date unless earlier terminated pursuant this article shall continue until nbsp expiration option period option been exercised nbsp option been exercised upon execution license agreement term style margin margin bottom text indent font size font family time roman termination breach style margin margin bottom text indent font size font family time roman notice either party belief that other material breach this agreement then breaching party deliver written notice such breach other party effective notice under this section nbsp written notice must nbsp explicitly reference this section nbsp nbsp explicitly state that breach cured notifying party will have right terminate this agreement allegedly breaching party shall have ninety nbsp from receipt such notice cure such breach provided that cure period shall thirty nbsp breach involving nonpayment amount hereunder style margin margin bottom text indent font size font family time roman failure cure party receiving notice breach fails cure such breach within such ninety nbsp period thirty nbsp period case payment breach party originally delivering notice terminate this agreement effective immediately upon delivery second written notice allegedly breaching party style margin margin bottom text indent font size font family time roman dispute party give notice termination under section nbsp other party dispute whether such notice proper then issue whether this agreement been terminated shall resolved accordance with article result such dispute resolution process determined that notice termination proper reason material breach agreement breaching party fails cure such material breach within applicable cure period after such determination then such termination shall deemed effective date notice termination result such dispute resolution process determined that notice termination improper then termination shall have occurred this agreement shall remain effect style margin margin bottom text indent font size font family time roman termination bankruptcy this agreement terminated either party immediately upon written notice other party extent permitted under applicable rule regulation upon filing institution bankruptcy reorganization liquidation receivership proceeding upon assignment substantial portion asset benefit creditor other party provided however that case involuntary bankruptcy proceeding such right terminate shall only become effective other party consent involuntary bankruptcy such proceeding dismissed within ninety nbsp after filing thereof style margin margin bottom text indent font size font family time roman termination patent challenge ophthotech affiliate sublicensees nbsp initiate request interference post grant review inter partes review reexamination protest opposition nullity similar proceeding with respect licensed patent nbsp make file maintains claim demand lawsuit cause action challenge validity enforceability licensed patent nbsp opposes extension grant supplementary protection certificate with respect licensed patent nbsp fund otherwise provides material assistance other person with respect foregoing aveo shall have right terminate this agreement upon thirty nbsp prior written notice ophthotech such termination shall only become effective ophthotech affiliate sublicensee applicable withdrawn such action before above notice period style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman elective termination during option period ophthotech shall have right sole discretion terminate this agreement entirety upon ninety nbsp prior written notice aveo style margin margin bottom text indent font size font family time roman effect termination upon expiration this agreement operation section nbsp termination this agreement aveo under section nbsp ophthotech under section nbsp subject term condition license agreement ophthotech exercise option style margin margin bottom text indent font size font family time roman option termination option shall terminate style margin margin bottom text indent font size font family time roman license license granted aveo ophthotech under article shall terminate license granted ophthotech aveo under article shall survive provided that nbsp license granted ophthotech aveo pursuant section nbsp shall expanded include safety data field nbsp such termination termination this agreement ophthotech pursuant section nbsp license granted ophthotech aveo section nbsp shall survive style margin margin bottom text indent font size font family time roman safety data ophthotech shall transfer aveo entire right title interest safety data style margin margin bottom text indent font size font family time roman ophthotech shall either sole discretion nbsp promptly terminate inds covering compound product containing compound nbsp promptly transfer such inds aveo style margin margin bottom text indent font size font family time roman aveo material ophthotech shall return aveo unused aveo material style margin margin bottom text indent font size font family time roman survival style margin margin bottom text indent font size font family time roman following provision related definition shall survive expiration termination this agreement section nbsp article article section nbsp this section nbsp article section nbsp section inclusive section inclusive style margin margin bottom text indent font size font family time roman expiration termination this agreement shall relieve party liability which accrued hereunder prior effective date such termination preclude either party from pursuing right remedy have hereunder equity with respect breach this agreement prejudice either party right obtain performance obligation style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center dispute resolution style margin margin bottom text indent font size font family time roman seeking consensus dispute controversy claim arising relating validity construction enforceability performance breach this agreement arises between party dispute then upon written request either party party shall have senior executive with decision making authority each party meet discus matter good faith written request shall explain nature dispute refer relevant provision agreement upon which dispute based complaining party shall also forth proposed solution problem including suggested time frame within which party must complaining party must respond writing within receiving notice with explanation including reference relevant provision agreement response proposed solution suggested time frame action complaining party must initiate scheduling this resolution meeting party shall have such senior executive other personnel necessary meet within after initial request writing either party party shall discus possible option resolving dispute including discussion whether mediation useful mechanism resolving dispute provided that neither party shall obligated enter into participate mediation matter resolved within following request discussion party have agreed upon mediation then either party then invoke arbitration accordance with this article mediation take place unsuccessful then either party then invoke arbitration accordance with this article style margin margin bottom text indent font size font family time roman arbitration style margin margin bottom text indent font size font family time roman notice arbitration dispute which arise between party that resolved pursuant section nbsp shall settled binding arbitration forth this section nbsp excluding patent dispute specified section nbsp which shall resolved pursuant section nbsp either party following period referenced section nbsp refer such issue arbitration submitting written notice such request other party style margin margin bottom text indent font size font family time roman selection arbitrator number arbitrator resolve dispute submitted arbitration under section nbsp shall three each party shall select nbsp arbitrator within following receipt notice under section nbsp arbitrator selected party shall responsible selecting third arbitrator each arbitrator shall neutral independent both party their respective affiliate shall have significant experience expertise licensing partnering agreement pharmaceutical biotechnology industry arbitrator selected party agree third arbitrator within following either party request arbitration hereunder then such third arbitrator shall appointed which arbitrator must meet foregoing criterion style margin margin bottom text indent font size font family time roman location proceeding place arbitration shall boston massachusetts proceeding shall conducted pursuant rule forth streamlined arbitration proceeding proceeding communication shall english each party shall have right represented counsel choosing style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman discovery party agree that discovery appropriate issue dispute shall permitted arbitration including reasonable document request hearing exchange information expert witness disclosure limited deposition important witness other appropriate discovery provided that such discovery shall limited narrower nbsp scope discovery agreed party none agreed established arbitrator nbsp such discovery would permitted federal rule civil procedure approved arbitrator keeping mind goal expedited efficient proceeding style margin margin bottom text indent font size font family time roman procedural rule statute limitation arbitration shall governed procedural substantive forth section nbsp statute limitation state york applicable commencement lawsuit shall apply commencement arbitration under this article provided that such statute limitation shall tolled with respect subject matter dispute upon delivery party written request under section nbsp relating such dispute provided further that senior executive unable resolve such dispute within period specified section nbsp party agree file notice arbitration within thereafter style margin margin bottom text indent font size font family time roman cost each party shall bear cost expense attorney arbitration except that arbitrator order prevailing party bear appropriate part reflective relative success issue cost expense reasonable attorney incurred prevailing party based relative merit each party position issue dispute party that substantially prevails arbitration proceeding shall paid arbitrator expense administrative arbitration style margin margin bottom text indent font size font family time roman award award rendered arbitrator shall final binding party shall governed term condition hereof including limitation damage forth section nbsp award paid party other party determined arbitrator cost incident enforcing award shall maximum extent permitted applicable charged against party resisting enforcement each party agrees abide award rendered arbitration conducted pursuant this article judgment entered upon final award court competent jurisdiction including court competent jurisdiction united state japan style margin margin bottom text indent font size font family time roman confidentiality proceeding decision arbitrator shall deemed confidential information each party shall subject article except required applicable neither party shall make instruct arbitrator make public announcement with respect proceeding decision arbitrator without prior written consent other party existence dispute submitted arbitration award shall kept confidence party arbitrator except required connection with enforcement such award otherwise required applicable style margin margin bottom text indent font size font family time roman survivability duty arbitrate under this agreement shall remain effect enforceable after termination this agreement reason style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman governing this agreement shall governed construed under substantive state york excluding conflict choice rule principle that might otherwise refer construction interpretation this agreement substantive another jurisdiction style margin margin bottom text indent font size font family time roman injunctive relief remedy breach exclusivity nothing this article will preclude either party from seeking equitable relief interim provisional relief from court competent jurisdiction including temporary restraining order preliminary injunction other interim equitable relief concerning dispute either prior during arbitration necessary protect interest such party preserve status pending arbitration proceeding specifically party agree that material breach either party obligation article this agreement cause irreparable harm other party which damage adequate remedy avoidance doubt nothing this section nbsp shall otherwise limit breaching party opportunity cure material breach permitted accordance with section nbsp style margin margin bottom text indent font size font family time roman patent dispute notwithstanding section nbsp dispute relating scope validity enforceability infringement patent shall submitted court competent jurisdiction country which such patent right were granted arose style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center miscellaneous style margin margin bottom text indent font size font family time roman export control this agreement made subject restriction concerning export product technical information from united state other country which imposed upon related aveo ophthotech from time time each party agrees that shall export directly indirectly technical information acquired from other party under this agreement product using such technical information location manner that time export requires export license other governmental approval without first obtaining written consent from appropriate agency other governmental entity style margin margin bottom text indent font size font family time roman entire agreement amendment this agreement including exhibit hereto forth complete final exclusive agreement covenant promise agreement warranty representation condition understanding between party hereto supersedes terminates prior agreement understanding between party including that certain confidential disclosure agreement between party effective february nbsp there covenant promise agreement warranty representation condition understanding either oral written between party other than forth herein therein subsequent alteration amendment change addition this agreement shall binding upon party unless reduced writing signed authorized officer each party style margin margin bottom text indent font size font family time roman bankruptcy right license granted under pursuant this agreement either party other shall deemed purpose section nbsp bankruptcy code license right intellectual property defined under section nbsp bankruptcy code each party agrees that other party licensee style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman such right under this agreement shall retain fully exercise right election under bankruptcy code without limiting foregoing party further agree that bankruptcy proceeding commenced against party debtor then event debtor reject this agreement pursuant section nbsp bankruptcy code otherwise applicable other party elect retain right hereunder pursuant section nbsp bankruptcy code otherwise applicable other party shall entitled complete duplicate complete access appropriate such intellectual property embodiment such intellectual property party further agree without limiting foregoing that unless until debtor reject this agreement pursuant applicable debtor shall perform obligation hereunder immediately provide other party complete duplicate complete access appropriate such intellectual property embodiment such intellectual property same already other party possession provided however that upon assumption this agreement debtor pursuant section nbsp bankruptcy code otherwise applicable other party shall promptly return such tangible material intellectual property embodiment thereof that have been provided solely result this section style margin margin bottom text indent font size font family time roman force majeure both party shall excused from performance their obligation under this agreement extent that such performance prevented force majeure nonperforming party promptly provides notice prevention other party such excuse shall continued long condition constituting force majeure continues nonperforming party take reasonable effort remove condition purpose this agreement force majeure mean condition beyond party reasonable control ability plan including terrorism civil commotion labor strike lock epidemic failure default public utility common carrier destruction production facility material fire earthquake storm like catastrophe provided however payment invoice owing hereunder shall excused reason force majeure affecting payor style margin margin bottom text indent font size font family time roman notice notice required permitted given under this agreement shall writing shall specifically refer this agreement shall deemed have been sufficiently given purpose mailed first class certified registered mail postage prepaid express delivery service personally delivered unless otherwise specified writing mailing address party shall described below style margin margin bottom margin left text indent font size font family time roman ophthotech style margin margin bottom margin left text indent font size font family time roman ophthotech corporation style margin margin bottom margin left text indent font size font family time roman penn plaza style font size vertical align floor style margin margin bottom margin left text indent font size font family time roman york york style margin margin bottom margin left text indent font size font family time roman attention chief executive officer style margin margin bottom margin left text indent font size font family time roman copy general counsel style margin margin bottom margin left text indent font size font family time roman facsimile nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left text indent font size font family time roman with required copy style margin margin bottom margin left text indent font size font family time roman wilmerhale style margin margin bottom margin left text indent font size font family time roman state street style margin margin bottom margin left text indent font size font family time roman boston massachusetts style margin margin bottom margin left text indent font size font family time roman attention steven barrett style margin margin bottom margin left text indent font size font family time roman facsimile nbsp style margin margin bottom margin left text indent font size font family time roman case aveo style margin margin bottom margin left text indent font size font family time roman aveo pharmaceutical style margin margin bottom margin left text indent font size font family time roman east kendall street style margin margin bottom margin left text indent font size font family time roman cambridge massachusetts style margin margin bottom margin left text indent font size font family time roman attention chief executive officer style margin margin bottom margin left text indent font size font family time roman copy general counsel style margin margin bottom margin left text indent font size font family time roman facsimile nbsp style margin margin bottom margin left text indent font size font family time roman with required copy style margin margin bottom margin left text indent font size font family time roman choate hall nbsp stewart style margin margin bottom margin left text indent font size font family time roman international place style margin margin bottom margin left text indent font size font family time roman boston massachusetts style margin margin bottom margin left text indent font size font family time roman attention gerald quirk style margin margin bottom margin left text indent font size font family time roman facsimile nbsp style margin margin bottom text indent font size font family time roman maintenance record each party shall keep maintain record required regulation with respect licensed product shall make copy such record available other party upon request style margin margin bottom text indent font size font family time roman construction this agreement been prepared jointly shall strictly construed against either party reference this agreement article section subsection paragraph clause exhibit shall deemed reference article section subsection paragraph clause exhibit case this agreement except where context otherwise requires nbsp definition reference agreement instrument other document refers such agreement instrument other document from time time amended supplemented otherwise modified subject restriction such amendment supplement modification forth herein therein nbsp reference refers such from time time enacted repealed amended nbsp word herein hereof hereunder word similar import refer this agreement entirety particular provision hereof nbsp word include includes including shall deemed followed phrase limited without limitation word similar import nbsp word inclusive meaning represented phrase nbsp word date hereof refers effective date nbsp word extent phrase extent mean degree which subject other thing extends such phrase mean simply nbsp definition contained this agreement applicable singular well plural form such term style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman ambiguity ambiguity this agreement shall construed against party irrespective which party deemed have authored ambiguous provision style margin margin bottom text indent font size font family time roman assignment neither this agreement right obligation hereunder assigned otherwise transferred party without consent other party provided however that party without such consent assign this agreement nbsp respective affiliate provided that such party shall remain primarily liable obligation assigned nbsp connection with sale transfer substantially such party business asset relating subject matter this agreement whether merger sale asset sale stock otherwise event each party agrees that notwithstanding provision this agreement contrary this agreement assigned party connection with event such assignment shall provide assigning party with right access intellectual property technology acquirer business asset assigning party permitted assignment shall binding successor assigning party assignment attempted assignment either party violation term this section nbsp shall null void style margin margin bottom text indent font size font family time roman performance affiliate each party acknowledges that obligation under this agreement performed affiliate other party each party hereby guarantee performance this agreement affiliate style margin margin bottom text indent font size font family time roman independent contractor expressly agreed that aveo ophthotech shall independent contractor that relationship between them shall constitute partnership joint venture agency neither aveo ophthotech shall have authority make statement representation commitment kind take action which shall binding other party without prior written consent other party style margin margin bottom text indent font size font family time roman counterpart this agreement executed nbsp more counterpart each which shall deemed original which together shall constitute same instrument signature page exchanged electronically portable document format form style margin margin bottom text indent font size font family time roman severability provision this agreement held invalid unenforceable alternative dispute resolution proceeding specified article from which court appeal taken provision shall considered severed from this agreement shall serve invalidate remaining provision hereof party shall make good faith effort replace invalid unenforceable provision with valid enforceable such that objective contemplated party when entering this agreement realized style margin margin bottom text indent font size font family time roman heading heading each article section this agreement have been inserted convenience reference only intended limit expand meaning language contained particular article section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman waiver delay enforcing party right under this agreement waiver particular default other matter shall constitute waiver such party right subsequent enforcement right under this agreement excepting only express written signed waiver particular matter particular period time executed authorized officer waiving party style margin margin bottom text indent font size font family time roman third party beneficiary except expressly forth this agreement third party shall deemed intended third party beneficiary hereunder have right enforce obligation this agreement style margin margin bottom text indent font size font family time roman cost each party shall bear legal cost incidental preparation negotiation execution this agreement style margin margin bottom font size font family time roman align center signature page follows style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman witness whereof ophthotech aveo have caused this agreement executed their duly authorized officer effective date style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size width valign bottom width width valign bottom width width valign bottom width valign bottom width width style font family time roman font size valign colspan ophthotech corporation valign bottom valign valign bottom valign colspan aveo pharmaceutical style font size height height colspan height colspan height colspan height colspan style font family time roman font size valign valign bottom style border bottom solid valign style border bottom solid david guyer valign bottom valign valign bottom valign valign bottom style border bottom solid valign style border bottom solid tuan ngoc style font family time roman font size valign name valign bottom valign david guyer valign bottom valign valign bottom valign name valign bottom valign bottom tuan ngoc style font family time roman font size valign title valign bottom valign chief executive officer valign bottom valign valign bottom valign title valign bottom valign bottom president nbsp chief executive officer table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center signature page research exclusive option agreement style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center aveo material style margin margin bottom font size font family time roman align center specification tivozanib hydrochloride yonezawa hamari chemical style margin margin bottom font size font family time roman specification tivozanib hydrochloride drug substance provided forth below style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman test valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid analytical nbsp procedure valign bottom nbsp valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid acceptance nbsp criterion style font size vertical align valign bottom nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign table table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left style font size vertical align nbsp align left valign assay result determined weight basis relative reference standard table table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left style font size vertical align nbsp align left valign percent unit specified impurity basis percent unit unspecified impurity percent area basis table style margin margin bottom font size font family time roman align center above specification intended drug substance used oral formulation style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center matter style margin margin bottom font size font family time roman style margin margin bottom font size font family time roman style margin margin bottom font size font family time roman ensuring necessary that ophthotech shall have right further sublicense ophthotech deems necessary desirable develop manufacture commercialize product containing tivozanib outside excluded territory field develop manufacture such product excluded territory commercialization outside excluded territory field style margin margin bottom font size font family time roman modifying right review participate regulatory filing meeting with regulatory authority style margin margin bottom font size font family time roman including stand license from ophthotech providing continuing license ophthotech event that agreement terminates reason other than ophthotech breach obligation under license agreement style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center license agreement term style margin margin bottom font size font family time roman understood agreed that foregoing provision revised result negotiation agreement amendment foregoing provision also modified upon mutual agreement party style margin margin bottom font size font family time roman licensed product will mean nbsp final formulation compound nbsp ocular administration nbsp upon subsequent written agreement aveo following request ophthotech oral administration each case either alone combination with nbsp more therapeutically active substance style margin margin bottom font size font family time roman financial provision style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width valign bottom width width style font family time roman font size valign development valign bottom colspan valign bottom style font family time roman font size valign milestone valign bottom valign bottom colspan license agreement will provide that within achievement each following development milestone with respect licensed product field ophthotech will following first time actual achievement time milestone payment each indication dollar style font size height height colspan height colspan height colspan bgcolor cceeff style font family time roman font size valign valign bottom valign bottom style margin left text indent font size font family time roman meeting efficacy safety endpoint phase clinical trial designed generate sufficient data allow assessment proof concept regulatory requirement support commencement phase clinical trial valign bottom valign bottom valign bottom align right nowrap valign bottom nbsp nbsp valign bottom valign bottom style font family time roman font size valign valign bottom valign bottom marketing approval valign bottom valign bottom valign bottom align right nowrap valign bottom nbsp nbsp valign bottom valign bottom bgcolor cceeff style font family time roman font size valign valign bottom valign bottom style margin left text indent font size font family time roman marketing approval france spain italy germany valign bottom valign bottom valign bottom align right nowrap valign bottom nbsp nbsp valign bottom valign bottom style font size height height colspan style font family time roman font size valign sale nbsp milestone valign bottom valign bottom colspan license agreement will provide that within achievement each following time sale milestone with respect licensed product ophthotech will following style font size height height colspan height colspan height colspan bgcolor cceeff style font family time roman font size valign valign bottom valign bottom annual sale exceed valign bottom valign bottom valign bottom align right nowrap valign bottom nbsp nbsp valign bottom valign bottom style font family time roman font size valign valign bottom valign bottom annual sale exceed valign bottom valign bottom valign bottom align right nowrap valign bottom nbsp nbsp valign bottom valign bottom style font size height height colspan height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman royalty valign bottom valign bottom ophthotech will tiered royalty worldwide annual sale licensed product described below method calculation reporting auditing sale will specified license agreement valign bottom valign bottom valign bottom valign bottom valign bottom valign bottom style font size height height colspan height colspan height colspan bgcolor cceeff style font family time roman font size valign valign bottom valign bottom portion sale font style font family symbol font valign bottom valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom valign bottom style font family time roman font size valign valign bottom valign bottom portion sale valign bottom valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom valign bottom bgcolor cceeff style font family time roman font size valign valign bottom valign bottom portion sale valign bottom valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom valign bottom style font family time roman font size valign valign bottom valign bottom portion sale valign bottom valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp valign bottom valign bottom table style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width style font size height height colspan style font family time roman font size valign valign bottom valign bottom colspan license agreement will include term negotiated party providing adjustment royalty payable aveo licensed product containing more than active ingredient style font size height height colspan style font family time roman font size valign third party valign bottom colspan valign bottom style font family time roman font size valign license valign bottom valign bottom colspan license agreement will include royalty offset clause negotiated party amount paid third party license right relating licensed product style font size height height colspan style font family time roman font size valign valign bottom valign bottom colspan aveo will remain responsible payment royalty obligation third party relating licensed technology existing effective date license agreement that sublicensed ophthotech such payment will made aveo accordance with term license agreement style font size height height colspan style font family time roman font size valign royalty term valign bottom valign bottom colspan negotiated style font size height height colspan style font family time roman font size valign expiration valign bottom colspan valign bottom style font family time roman font size valign royalty nbsp term valign bottom valign bottom colspan following royalty term country country basis license granted ophthotech with respect licensed technology compound will become fully paid licensable royalty free transferable perpetual irrevocable license continuing beyond term license agreement style font size height colspan height colspan style font family time roman font size valign colspan operational term valign bottom valign bottom style font size height height colspan style font family time roman font size valign development valign bottom valign bottom colspan ophthotech will commercially reasonable effort conduct activity development compound accordance with written development plan development plan development plan will agreed upon party will attached license agreement provided that license agreement shall include provision permitting ophthotech reasonably update amend development plan throughout course development activity ophthotech will responsible development cost clinical study clinical work included development plan style font size height height colspan style font family time roman font size valign regulatory valign bottom valign bottom colspan ophthotech will solely responsible cost obtaining required permit authorization from regulatory authority conduct clinical study development plan development commercialization licensed product field option period research territory using commercially reasonable effort obtain maintain marketing authorization approval licensed product field least certain major country option period research territory specified license agreement table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign commercialization valign bottom valign bottom ophthotech affiliate sublicensees authorized agent will solely responsible using commercially reasonable effort commercialize licensed product option period research territory field including manufacturing marketing sale activity distribution pricing reimbursement booking sale ophthotech will result commercialization activity such trademark related thereto style font size height height colspan style font family time roman font size valign manufacturing valign bottom valign bottom ophthotech will responsible supply compound activity conducted under license agreement unless otherwise agreed party table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center option period research style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center press release form disclosure style margin margin bottom font size font family time roman press release style margin margin bottom font size font family time roman align center aveo enters into research exclusive option agreement with ophthotech tivozanib style margin margin bottom font size font family time roman align center vegf inhibitor treatment ocular disease style margin margin bottom font size font family time roman cambridge mass aveo oncology nasdaq aveo today announced that entered into research exclusive option agreement with ophthotech corporation under which provided ophthotech exclusive license investigate potential aveo small molecule vascular endothelial growth factor vegf tyrosine kinase inhibitor tivozanib outside asia potential treatment oncologic disease style margin margin bottom font size font family time roman under term agreement ophthotech obligated aveo upfront option investigate tivozanib potential treatment oncologic disease during option term ophthotech elect continue development ocular formulation tivozanib after initial analysis aveo eligible receive million milestone payment based upon achievement specified research development business goal ophthotech exclusive option exercisable sole discretion obtain additional development commercialization right tivozanib product containing tivozanib oncologic indication territory outside asia subject certain condition including outcome proof concept clinical trial negotiation definitive license agreement style margin margin bottom font size font family time roman ophthotech exercise option aveo would receive option exercise million could also receive clinical regulatory based milestone payment million sale based milestone payment million royalty product sale ophthotech responsible research development activity cost upon exercise option further development commercialization activity cost tivozanib ocular indication percentage upfront milestone royalty payment received aveo kyowa hakko kirin sublicensing style margin margin bottom font size font family time roman this agreement another example execution against aveo strategic objective advancing pipeline asset through external resource expertise stated tuan ngoc president chief executive officer aveo believe unique property tivozanib make ideal vegf inhibitor potential ocular encouraged ophthotech interest exploring this potential this agreement could enable realize value tivozanib indication outside cancer while retaining oncology right further development through additional potential partnership style margin margin bottom font size font family time roman about aveo style margin margin bottom font size font family time roman aveo oncology nasdaq aveo biopharmaceutical company committed discovering developing targeted therapy designed provide substantial impact life people with cancer addressing unmet medical need aveo proprietary human response platform provides company unique insight into cancer related disease biology being leveraged discovery clinical development therapeutic candidate more information please visit company website aveooncology style page break before always size style color width align center style margin margin bottom font size font family time roman cautionary note regarding forward looking statement style margin margin bottom font size font family time roman this press release contains forward looking statement aveo within meaning private security litigation reform that involve substantial risk uncertainty statement other than statement historical fact contained this press release forward looking statement word anticipate believe estimate expect intend plan target potential could should seek negative these term other similar expression intended identify forward looking statement although forward looking statement contain these identifying word these forward looking statement include among others statement about payment that received aveo under both option agreement future license agreement with ophthotech potential development tivozanib ocular disease potential aveo realize value tivozanib indication outside cancer further develop tivozanib cancer indication through additional partnership actual result event could differ materially from plan intention expectation disclosed forward looking statement that aveo make number important factor including risk relating ophthotech ability willingness successfully develop tivozanib oncologic disease including risk that ophthotech elect exercise option enter into license agreement with aveo further develop tivozanib this indication aveo ability execute business strategy enter into maintain strategic partnership collaboration agreement aveo ability successfully enroll complete clinical trial preclinical study product candidate aveo ability demonstrate satisfaction equivalent foreign regulatory agency safety efficacy clinically meaningful benefit product candidate aveo ability achieve maintain compliance with regulatory requirement applicable product candidate aveo ability obtain maintain adequate protection intellectual property right relating product candidate technology development expense related aveo ongoing shareholder litigation inquiry aveo ability raise substantial additional fund required achieve goal unplanned capital requirement adverse general economic industry condition competitive factor those risk discussed section titled risk factor included aveo most recent quarterly report form other filing with forward looking statement this press release represent aveo view date this press release aveo anticipates that subsequent event development will cause view change however while aveo elect update these forward looking statement some point future specifically disclaims obligation should therefore rely these forward looking statement representing aveo view date subsequent date this press release style margin margin bottom font size font family time roman company medium investor contact style margin margin bottom font size font family time roman david pitt argot partner style margin margin bottom font size font family time roman style margin margin bottom font size font family time roman aveo argotpartners style margin margin bottom font size font family time roman align center style margin margin bottom font size font family time roman form disclosure style margin margin bottom font size font family time roman entry into definitive material agreement style margin margin bottom text indent font size font family time roman november nbsp effective date aveo pharmaceutical delaware corporation aveo entered into research exclusive option agreement option agreement with ophthotech corporation delaware corporation ophthotech pursuant which style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman aveo provided ophthotech exclusive option enter into definitive license agreement option under which aveo would grant ophthotech right develop commercialize aveo small molecule vascular endothelial growth factor tyrosine kinase inhibitor tivozanib outside asia potential diagnosis prevention treatment oncologic disease condition human style margin margin bottom text indent font size font family time roman aveo granted ophthotech exclusive royalty free license sublicense applicable under intellectual property right controlled aveo solely perform research development activity related tivozanib forth development plan during option period defined below these activity include formulation work ocular administration preclinical research conduct phase proof concept clinical trial product containing tivozanib patient with related macular degeneration study style margin margin bottom text indent font size font family time roman ophthotech required aveo within effective date consideration grant option aveo obligated make available ophthotech cost ophthotech certain quantity tivozanib hydrochloride including manufacturing additional quantity tivozanib event stability data indicates that current supply will expire prior february style margin margin bottom text indent font size font family time roman during option period ophthotech elect continue development tivozanib oncologic disease aveo entitled receive million upon acceptance first investigational drug application purpose conducting human clinical study tivozanib ocular disease submission milestone payment aveo also entitled receive million clinical efficacy milestone payment earlier nbsp december nbsp nbsp later occur nbsp achievement clinical milestone study clinical efficacy milestone nbsp earlier nbsp date twelve nbsp month after party agreement form substance amendment defined below nbsp date ninety nbsp after entry into amendment subject ophthotech right terminate option agreement written notice date which such payment clinical efficacy milestone payment trigger date style margin margin bottom text indent font size font family time roman ophthotech exercise option time until latest occur nbsp twelve nbsp month after achievement clinical efficacy milestone nbsp ninety nbsp after clinical efficacy milestone payment trigger date nbsp thirty nbsp after aveo ophthotech agree definitive form license agreement option period style margin margin bottom text indent font size font family time roman during option period aveo will grant license third party that would preclude aveo from being able grant ophthotech right license that contemplated definitive license agreement aveo will engage research development commercialization tivozanib field covered contemplated definitive license agreement except specified option agreement style margin margin bottom text indent font size font family time roman term option agreement subject aveo obligation kyowa hakko kirin under license agreement entered into aveo with pursuant which aveo acquired exclusive right develop commercialize tivozanib human disease outside asia license agreement percentage payment received aveo under option agreement definitive license agreement must paid aveo required maintain agreement effect enter into amendment termination thereof that would adversely affect opthotech right during option period style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman during option period aveo ophthotech obligated negotiate good faith form substance definitive license agreement well form substance amendment license agreement amendment modify certain right obligation party sublicensees thereunder particularly with respect right improvement that specifically related tivozanib regulatory affair matter style margin margin bottom text indent font size font family time roman upon exercise option ophthotech required aveo million addition submission milestone payment such payment then been previously paid upon exercise option clinical efficacy milestone payment trigger date occurred aveo shall entitled clinical efficacy milestone payment such time that clinical efficacy milestone payment date occur license agreement remains effect such date license agreement entered into upon ophthotech exercise option will provide aveo entitled receive nbsp million upon meeting certain efficacy safety endpoint phase clinical trial that would enable commencement phase clinical trial nbsp million upon marketing approval united state nbsp million upon marketing approval germany spain italy france nbsp million sale based milestone payment ophthotech would also required tiered double digit royalty teen sale tivozanib product containing tivozanib style margin margin bottom text indent font size font family time roman either party terminate option agreement event uncured material breach option agreement other party which remains uncured period ninety nbsp thirty nbsp breach relating payment upon bankruptcy like proceeding relating other party ophthotech terminate option agreement time upon ninety nbsp prior written notice aveo addition aveo terminate option agreement upon thirty nbsp prior written notice ophthotech ophthotech challenge certain patent controlled aveo related tivozanib unless terminated provided above option agreement will expire upon expiration option period entry into definitive license agreement style margin margin bottom text indent font size font family time roman foregoing summary option agreement purport complete qualified entirety full text option agreement which aveo intends file exhibit future filing with security exchange commission style margin margin bottom font size font family time roman other event style margin margin bottom text indent font size font family time roman november nbsp aveo issued press release announcing entry into option agreement described item nbsp above copy press release attached exhibit this current report form incorporated herein reference style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center body html text document